Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

No Thumbnail Available
File version
Author(s)
Ribi, Karin
Luo, Weixiu
Colleoni, Marco
Karlsson, Per
Chirgwin, Jacquie
Aebi, Stefan
Jerusalem, Guy
Neven, Patrick
Di Lauro, Vincenzo
Gomez, Henry L
Ruhstaller, Thomas
Abdi, Ehtesham
Biganzoli, Laura
Müller, Bettina
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location
License
Abstract

The ClinicalTrials.gov Identifier was incorrectly listed as NCT00651456. The correct identifier is listed below.

Clinical trial information

Clinical trial information: NCT00553410.

Journal Title

British Journal of Cancer

Conference Title
Book Title
Edition
Volume

122

Issue

7

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Oncology and carcinogenesis

Persistent link to this record
Citation

Ribi, K; Luo, W; Colleoni, M; Karlsson, P; Chirgwin, J; Aebi, S; Jerusalem, G; Neven, P; Di Lauro, V; Gomez, HL; Ruhstaller, T; Abdi, E; Biganzoli, L; Müller, B; et al., Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial., British Journal of Cancer, 2020, 122 (7), pp. 1119-

Collections